Abstract
Researchers from Miami, Florida, propose a new therapeutic strategy for castration-resistant prostate cancer (CRPC) in their study recently published online in PNAS. “Approximately 32,000 men in the USA die from advanced CRPC each year, yet no effective treatment is currently available,” explain Andrew Schally and Ferenc Rick, corresponding authors. “We have previously shown that antagonists of the hypothalamic growth hormone-releasing hormone (GHRH) can inhibit the growth of human CRPC xenografted into nude mice.” Now, the team have shown that a new GHRH antagonist, JMR-132, also inhibits growth of CRPC and have described its mechanism of action.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
